Nonplatinum therapy in advanced bladder cancer

Expert Review of Anticancer Therapy

Volumn 6, Issue 6, 2006, Pages 887-894

  Srinivas, Sandy ^a   Colocci, Natalia ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Advanced bladder cancer; Chemotherapy; Platinum

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CCI 225; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DIHYDROFOLATE REDUCTASE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERLOTINIB; FIBROBLAST GROWTH FACTOR; FLUOROURACIL; GEFITINIB; GEMCITABINE; METHOTREXATE; PACLITAXEL; PEMETREXED; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN BCL 2; PROTEIN P53; PURINE; PYRIMIDINE; RAF PROTEIN; SORAFENIB; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN; VINBLASTINE; ANTINEOPLASTIC AGENT; VASCULOTROPIN A;

ADVANCED CANCER; AREA UNDER THE CURVE; BLADDER CANCER; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG RESPONSE; HUMAN; KIDNEY DYSFUNCTION; LUNG TOXICITY; METASTASIS POTENTIAL; NONHUMAN; PREVALENCE; PROGNOSIS; REVIEW; UNITED STATES; UROGENITAL TRACT CANCER; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BLADDER TUMOR; DRUG ANTAGONISM; DRUG CONTRAINDICATION; PATHOLOGY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; HUMANS; NEOADJUVANT THERAPY; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85047698249     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.6.887     Document Type: Review

References (71)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J. Clin. 56, 106-130 (2006).
2. Panani AD, Ferti AD, Raptis SA, Roussos C. Novel recurrent structural chromosomal aberrations in primary bladder cancer. Anticancer Res. 24, 2967-2974 (2004).
3. Pollack A, Wu CS, Czerniak B et al. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Clin. Cancer Res. 3, 1823-1829 (1997).
4. Cordon-Cardo C, Wartinger D, Petrylak D et al. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J. Natl Cancer Inst. 84, 1251-1256 (1992).
5. Cordon-Cardo C, Zhang ZF, Dalbagni G et al. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res. 57, 1217-1221 (1997).
6. Neal DE, Sharples L, Smith K et al. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 65, 1619-1625 (1990).
7. Miyamoto H, Kubota Y, Noguchi S et al. C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer. Urology 55, 679-683 (2000).
8. Al-Sukhun S, Hussain M. Current understanding of the biology of advanced bladder cancer. Cancer 97, 2064-2075 (2003).
9. Dickinson AJ, Fox SB, Persad RA et al. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br. J. Urol. 74, 762-766 (1994).
10. Loehrer PJ Sr, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 10, 1066-1073 (1992).
11. Bajorin DF, Dodd PM, Mazumdar M et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J. Clin. Oncol. 17, 3173-3181 (1999).
12. Geller NL, Sternberg CN, Penenberg D, Scher H, Yagoda A. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer 67, 1525-1531 (1991).
13. Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP. Biology and management of bladder cancer. N. Engl. J. Med. 322, 1129-1138 (1990).
14. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J. Urol. 155, 495-500 (1996).
15. Lehmann J, Retz M, Wiemers C et al. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J. Clin. Oncol. 23, 4963-4974 (2005).
16. Skinner DG, Daniels JR, Russell CA et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J. Urol. 145, 459-457 (1991).
17. Stockle M, Meyenburg W, Wellek S et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J. Urol. 148, 302-307 (1992).
18. Studer UE, Bacchi M, Biedermann C et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J. Urol. 152, 81-84 (1994).
19. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 354, 533-540 (1999).
20. Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859-866 (2003).
21. Malmstrom PU, Rintala E, Wahlqvist R et al. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J. Urol. 155, 1903-1906 (1996).
22. Martinez-Pineiro JA, Gonzalez Martin M, Arocena F et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J. Urol. 153, 964-973 (1995).
23. Sengelov L, von der Maase H, Lundbeck F et al. Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours. Acta Oncol. 41, 447-456 (2002).
24. Sherif A, Rintala E, Mestad O et al. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer - Nordic Cystectomy Trial 2. Scand. J. Urol. Nephrol. 36, 419-425 (2002).
25. Shipley WU, Winter KA, Kaufman DS et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J. Clin. Oncol. 16, 3576-3583 (1998).
26. Wallace DM, Raghavan D, Kelly KA et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br. J. Urol. 67, 608-615 (1991).
27. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361, 1927-1934 (2003).
28. Winquist E, Kirchner TS, Segal R, Chin J, Lukka H. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J. Urol. 171, 561-569 (2004).
29. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol. 18, 3068-3077 (2000).
30. Nogue-Aliguer M, Carles J, Arrivi A et al. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer 97, 2180-2186 (2003).
31. Bellmunt J, de Wit R, Albanell J, Baselga J. A feasibility study of carboplatin with fixed dose of gemcitabine in 'unfit' patients with advanced bladder cancer. Eur. J. Cancer 37, 2212-2215 (2001).
32. Redman BG, Smith DC, Flaherty L, Du W, Hussain M. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J. Clin. Oncol. 16, 1844-1848 (1998).
33. Zielinski CC, Schnack B, Grbovic M et al. Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trial. Br. J. Cancer 78, 370-374 (1998).
34. Vaughn DJ, Malkowicz SB, Zoltick B et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J. Clin. Oncol. 16, 255-260 (1998).
35. Small EJ, Lew D, Redman BG et al. Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J. Clin. Oncol. 18, 2537-2544 (2000).
36. Friedland DM, Dakhil S, Hollen C. Gregurich MA, Asmar L. A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer. Cancer Invest. 22, 374-382 (2004).
37. Vaughn DJ, Manola J, Dreicer R et al Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group. Cancer 95, 1022-1027 (2002).
38. Carteni G, Dogliotti L, Crucitta E et al. Phase II randomised trial of gemcitabine plus cisplatin(GP) and gemcitabine plus carboplatin(GC) in patients with advanced or metastatic transtional cell carcinoma of the urothelium(TCCU). Proc. Am. Soc. Clin. Oncol. 22, 384 (2003).
39. Petrioli R, Frediani B, Manganelli A et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. Cancer 77, 344-351 (1996).
40. Bellmunt J, Ribas A, Eres N et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80, 1966-1972 (1997).
41. Dreicer R, Manola J, Roth BJ et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 100, 1639-1645 (2004).
42. Wang GS, Yang KY, Perng RP Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere). Br. J. Cancer 85, 1247-1250 (2001).
43. Read WL, Mortimer JE, Picus J. Severe interstitial pneumonitis associated with docetaxel administration. Cancer 94, 847-853 (2002).
44. Khan A, McNally D, Tutschka PJ, Bilgrami S. Paclitaxel-induced acute bilateral pneumonitis. Ann. Pharmacother. 31, 1471-1474 (1997).
45. Thomas AL, Cox G, Sharma RA et al. Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study. Eur. J. Cancer 36, 2329-2334 (2000).
46. Kouroussis C, Mavroudis D, Kakolyris S et al. High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. Lung Cancer 44, 363-368 (2004).
47. Meluch AA, Greco FA, Burris HA III et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl Cancer Research network. J. Clin. Oncol. 19, 3018-3024 (2001).
48. Kaufman DS, Carducci MA, Kuzel TM et al. A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol. Oncol. 22, 393-397 (2004).
49. Li J, Juliar B, Yiannoutsos C et al. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J. Clin. Oncol. 23, 1185-1191 (2005).
50. Srinivas S, Guardino AE. A nonplatinum combination in metastatic transitional cell carcinoma. Am. J. Clin. Oncol. 28, 114-118 (2005).
51. Ardavanis A, Tryfonopoulos D, Alexopoulos A et al. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study. Br. J. Cancer 92, 645-650 (2005).
52. Gitlitz BJ, Baker C, Chapman Y et al. A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer 98, 1863-1869 (2003).
53. Ricci S, Galli L, Chioni A et al. Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens. Cancer 95, 1444-1450 (2002).
54. Paz-Ares L, Bezares S, Tabernero JM, Castellanos D, Cortes-Funes H. Review of a promising new agent - pemetrexed disodium. Cancer 97, 2056-2063 (2003).
55. Hill BT, Fiebig HH, Waud WR et al. Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur. J. Cancer 35, 512-520 (1999).
56. Bui B, Theodore C, Culine S et al. Preliminary results of a phase II study testing intravenous (iv) vinflunine (VFL) as second line therapy in patients with advanced transitional cell cancer (TCC) of the bladder. Proc. Am. Soc. Clin. Oncol. 22, 1571 (2003).
57. Inoue K, Slaton JW, Perrotte P et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin. Cancer Res. 6, 4874-4884 (2000).
58. Rosenberg JE, Carroll PR, Small EJ. Update on chemotherapy for advanced bladder cancer. J. Urol. 174, 14-20 (2005).
59. Bellmunt J, Hussain M, Dinney CP. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit. Rev. Oncol. Hematol. (Suppl. 46), S85-S104 (2003).
60. Small EJ, Halabi S, Dalbagni G et al. Overview of bladder cancer trials in the Cancer and Leukemia Group B. Cancer 97, 2090-2098 (2003).
61. Jimenez RE, Hussain M, Bianco FJ Jr et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin. Cancer Res. 7, 2440-2447 (2001).
62. Coogan CL, Estrada CR, Kapur S, Bloom KJ. HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. Urology 63, 786-790 (2004).
63. Hussain M, Petrylak DP, Dunn R et al. Trastuzumab(T), paclitaxel(P), carboplatin(C), and gemcitabine(G) in advanced HER2-positive urothelial carcinoma: results of a multi-center phase II NCI trial. Proc. Am. Soc. Clin. Oncol. 24 (2005).
64. Peyromaure M, Scotte F, Amsellem-Ouazana D et al. Trastuzumab (Herceptin) in metastatic transitional cell carcinoma of the urinary tract: report on six patients. Eur. Urol. 48, 771-778 (2005).
65. Hillcoat BL, Raghavan D, Matthews J et al. A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. J. Clin. Oncol. 7, 706-709 (1989).
66. Logothetis CJ, Dexeus FH, Finn L et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol. 8, 1050-1055 (1990).
67. Sternberg CN, de Mulder PH, Schornagel JH et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J. Clin. Oncol. 19, 2638-2646 (2001).
68. Siefker-Radtke AO, Millikan RE, Tu SM et al. Phase III trial of fluorouracil, interferon α-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J. Clin. Oncol. 20, 1361-1367 (2002).
69. Bamias A, Aravantinos G, Deliveliotis C et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J. Clin. Oncol. 22, 220-228 (2004).
70. Neri B, Doni L, Fulignati C et al. Gemcitabine plus Epi-doxorubicin as first-line chemotherapy for bladder cancer in advanced or metastatic stage: a phase II. Anticancer Res. 22, 2981-2984 (2002).
71. Turkolmez K, Beduk Y, Baltaci S, Gogus C, Gogus O. Gemcitabine plus vinorelbine chemotherapy in patients with advanced bladder carcinoma who are medically unsuitable for or who have failed cisplatin-based chemotherapy. Eur. Urol. 44, 682-686 (2003).